RSV-F Vaccine + Phosphate Buffer Placebo
Phase 3Completed 0 watching 0 views this week📈 Rising
72
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Respiratory Syncytial Virus (RSV)
Conditions
Respiratory Syncytial Virus (RSV)
Trial Timeline
Nov 1, 2015 → Dec 1, 2016
NCT ID
NCT02608502About RSV-F Vaccine + Phosphate Buffer Placebo
RSV-F Vaccine + Phosphate Buffer Placebo is a phase 3 stage product being developed by Novavax for Respiratory Syncytial Virus (RSV). The current trial status is completed. This product is registered under clinical trial identifier NCT02608502. Target conditions include Respiratory Syncytial Virus (RSV).
Hype Score Breakdown
Clinical
27
Activity
18
Company
5
Novelty
9
Community
10
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02608502 | Phase 3 | Completed |
| NCT02593071 | Phase 2 | Completed |
Competing Products
20 competing products in Respiratory Syncytial Virus (RSV)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Zopapogene imadenovec (Zopa) | Precigen | Approved | 80 |
| PRGN-2012 - Phase I; Dose Level 1 + PRGN-2012 - Phase I; Dose Level 2 + PRGN-2012 - Phase II; Dose Level 2 | Precigen | Phase 1/2 | 36 |
| agenT-797 | MiNK Therapeutics | Phase 1 | 25 |
| YMC026 + Placebo | Yuhan | Approved | 85 |
| VN-0200 + Placebo | Daiichi Sankyo | Phase 1 | 33 |
| VN-0200 | Daiichi Sankyo | Phase 2 | 52 |
| Isavuconazonium Injection [Cresemba] + Placebo | Astellas Pharma | Phase 3 | 77 |
| S-337395 + Placebo | Shionogi | Phase 2 | 52 |
| Sivelestat | Eli Lilly | Phase 1/2 | 41 |
| Itolizumab IV infusion + Best supportive care (BSC) | Biocon | Phase 2 | 52 |
| Paracetamol 500 mg/Phenylephrine 5 mg tablets + Paracetamol 1000 mg/Phenylephrine 10 mg sachet | Johnson & Johnson | Phase 1 | 33 |
| Mesenchymal stem cell | Rohto Pharmaceutical | Phase 1 | 33 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Palivizumab | AbbVie | Phase 3 | 77 |
| Placebo + AZD5634 | AstraZeneca | Phase 1 | 33 |
| MEDI8897 + Palivizumab | AstraZeneca | Phase 2/3 | 65 |
| Selumetinib + Durvalumab | AstraZeneca | Phase 2 | 52 |
| Tozorakimab + Placebo | AstraZeneca | Phase 3 | 77 |
| Nirsevimab | AstraZeneca | Phase 3 | 77 |
| Nirsevimab + Placebo | AstraZeneca | Phase 3 | 77 |
Other Products from Novavax
Novavax COVID-19 vaccine (2023-2024 formula XBB containing) + Pfizer COVID-19 mRNA vaccine (2023-2024 formula XBB containing)Approved
80
protein subunit: Novavax COVID-19 vaccine + Pfizer mRNA COVID-19 vaccineApproved
80
NVX-CoV2705 + PlaceboApproved
80
NVX-CoV2373 + BBIBP-CorV vaccinePhase 3
72
SARS-CoV-2 rS/Matrix-M1 Adjuvant (Initial Vaccination Period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Crossover Vaccination period) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Booster Vaccination) + SARS-CoV-2 rS/Matrix-M1 Adjuvant (Second Booster Vaccination)Phase 3
72